Abstract:OBJECTIVE: Typically diagnosed in early childhood or adolescence, TSC is a chronic, multisystemic disorder with age-dependent manifestations posing a challenge for transition and for specific surveillance throughout the lifetime. Data on the clinical features and severity of TSC in adults and on the prognosis of epilepsy are scarce. We analyzed the clinical and genetic features of a cohort of adult patients with TSC, to identify the prognostic predictors of seizure remission after a long follow-up.METHOD: We conducted a retrospective analysis of patients diagnosed with TSC according to the updated international diagnostic criteria. Pearson's chi-square or Fisher's exact test and Mann Whitney U test were used to compare variables among the Remission (R) and Non-Remission (NR) group. Univariate and multivariate logistic regression analyses were performed.RESULTS: We selected 43 patients with TSC and neurological involvement in terms of epilepsy and/or brain lesions, attending the Epilepsy Center of our Institute: of them, 16 (37.2%) were transitioning from the pediatric care and 6 (13.9%) were referred by other specialists. Multiorgan involvement includes cutaneous (86.0%), nephrological (70.7%), hepatic (40.0%), ocular (34.3%), pneumological (28.6%) and cardiac (26.3%) manifestations. Thirty-nine patients (90.7 %) had epilepsy. The mean age at seizure onset was 4 ± 7.3 years: most patients (29, 76.3 %) presented with focal seizures or spasms by age 3 years; only 2 (5.3 %) had seizure onset in adulthood. Twenty-seven patients (69.2 %) experienced multiple seizure types overtime, 23 (59.0 %) had intellectual disability (ID). At last assessment, 14 (35.9 %) were seizure free (R group) and 25 (64.1 %) had drug-resistant seizures (NR group). At logistic regression univariate analysis, ID (OR 7.9, 95 % CI 1.8--34.7), multiple seizure types lifelong (OR 13.2, 95 % CI 2.6- 67.2), spasms/tonic seizures at presentation (OR 6.5, 95 % CI 1.2--35.2), a higher seizure frequency at onset (OR 5.4, 95 % CI 1.2--24.3), abnormal neurological examination (OR 9.8, 95 % CI 1.1--90.6) and pathogenic variants in TSC2 (OR 5.4, 95 % CI 1.2--24.5) were significantly associated with non-remission. In the multivariate analysis, both ID and multiple seizure types lifelong were confirmed as independent predictors of poor seizure outcome.CONCLUSIONS: In our cohort of adult patients with TSC, epilepsy remains one of the main neurological challenges with only 5.3% of cases manifesting in adulthood. Approximately 64% of these patients failed to achieve seizure remission. ID and multiple seizure types were the main predictors of poor outcome. Nephrological manifestations require continuous specific follow-up in adults.

Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated with Tuberous Sclerosis Complex: Results from TOSCA Registry

Neurodevelopmental Outcomes of a Cohort of Children with Tuberous Sclerosis Complex with Epileptic Spasms

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?

Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex

Pathways to epilepsy surgery in children with tuberous sclerosis complex-associated epilepsy

Patients' and physicians' awareness of clinical symptoms and disease severity in tuberous sclerosis complex

Tuberous sclerosis complex in adulthood: focus on epilepsy prognosis

Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy

Severe Epilepsy in an Individual with a TSC2 R905Q Variant Prompting Late Diagnosis in Affected Family Members

A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits

Epileptic seizures revealing tuberous sclerosis in a tropical environment: A study of 12 case series

Rare Manifestations and Malignancies in Tuberous Sclerosis Complex: Findings from the TuberOus SClerosis Registry to Increase Disease Awareness (TOSCA)

Astroglial calcium signaling and homeostasis in tuberous sclerosis complex

The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases

Prenatal Diagnosis and Intervention Improve Developmental Outcomes and Epilepsy Prognosis in Children with Tuberous Sclerosis Complex

Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings from the TOSCA Study.

The clinical features of the patients with seizure secondary to tuberous sclerosis complex

Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial

Common epilepsy variants from the general population are not associated with epilepsy among individuals with tuberous sclerosis complex

Diagnosis of tuberous sclerosis in the prenatal period: a retrospective study of 240 cases and review of the literature

Accumulated seizure burden predicts neurodevelopmental outcome at 36 months of age in patients with tuberous sclerosis complex